As the number of new drug approvals surges worldwide, national healthcare systems face a pressing challenge: how to assess value and ensure equitable reimbursement. With more treatments emerging faster than ever before, the pressure is mounting on reimbursement systems to determine which therapies should be covered, for whom, and at what cost. In Taiwan, this … Rethinking Reimbursement: How Real-World Data Can Reshape the Future of Drug Access Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.